|
Diversified Employee Benefit Services, LLC |
 |
|
|
| Sign-up today to start receiving
The HCB Newsletter! |
 |
|
Meet S.A. HC+B Magazine |
 |
Welcome! to San Antonio's first healthcare and bioscience online community.
|
|
|
| Welcome!
To San Antonio's newest online healthcare and bioscience community and to The HCB Newsletter, feeder publication to the San Antonio Healthcare & Bioscience Magazine and website, www.hcbmagazine.com.
In this week's issue you'll find the latest news and stories on some of San Antonio's finest businesses and organizations who are helping to shape our healthcare community and guide San Antonio towards building a stronger national and global presence.
Have a safe and Happy Thanksgiving and see you next week.
Melba Romero
Publisher/Editor
S.A. Healthcare & Bioscience Magazine
P.S. Help spread the word about The HCB Newsletter to friends and collegues by clicking on the "Forward Email" button located at the bottom of this page. |
|
DPT Laboratories, Ltd. Receives Frost & Sullivan North American Healthcare Innovation Award |
 DPT Laboratories, Ltd., San Antonio, Texas - November 12, 2008DPT Laboratories, Ltd. received the 2008 North American Pharmaceutical Contract Research and Manufacturing Services Healthcare Innovation Award from Frost & Sullivan as part of the consulting firm's annual Best Practices Awards. Full Story. |
Methodist Healthcare System Hospitals Receive Hispanic Healthcare Designation |
 Methodist Healthcare System, San Antonio, TX - November 20, 2008The Diversity Health Care Institute of Mexico accredit Northeast Methodist Hospital and Methodist Ambulatory Surgery Hospital as Hispanic Healthcare Hospitals. Methodist is the only health care system in the United States to receive this distinction; these two hospitals now join Methodist Hospital, Methodist Specialty and Transplant Hospital and Metropolitan Methodist Hospital in acquiring this prestigious designation. The accreditation recognizes the efforts of Methodist Healthcare to make health care accessible to international and Spanish-speaking patients by removing cultural barriers. Dr. Enrique Ruelas Barajas, secretary of the Counsel on General Health Care in Mexico, announced the designations. Methodist Healthcare is the only health care system in the region with a dedicated International Services department to assist patients, physicians and staff in accessing healthcare services. Full Story. |
|
Dr. Randal Otto Named to New Leadership Position at CTRC |
 Cancer Therapy & Research Center at UT Health Science Center, San Antonio, TX - November 17, 2008Randal A. Otto , M.D., has been named physician in chief of the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio effective immediately, announced William L. Henrich, M.D, M.A.C.P., dean of the School of Medicine and vice president for medical affairs. Dr. Otto will be responsible for the CTRC's daily clinical operations, a role he has fulfilled on an interim basis since March 2008.A specialist in head and neck cancers, Dr. Otto is professor and chair of the department of otolaryngology, a post he has held for seven years, and the Thomas W. Folbre, M.D. Endowed Chair in Otolaryngology. In addition to his administrative and active surgical practice, Dr. Otto conducts innovative and translational cancer research. Full Story. |
| Genzyme Seeks U.S. Approval for ClolarŪ to Treat Adult AML |
 Genzyme Corporation, November 24, 2008
Genzyme Corporation (Nasdaq: GENZ) announced today that it has filed a supplemental New Drug Application with the U.S. Food and Drug Administration for the use of ClolarŪ (clofarabine) to treat adult patients with acute myeloid leukemia (AML). The company has requested priority review of its application and, if granted, Clolar could be approved for this indication in the first half of 2009. Clolar is currently approved in the United States and Europe for the treatment of acute lymphoblastic leukemia (ALL) in relapsed and refractory pediatric patients one to 21 years old who have received at least two prior treatments, and it is now a standard of care in this setting. Genzyme is developing clofarabine globally for the treatment of adult AML, earlier-line pediatric ALL, and myelodysplastic syndromes (MDS), broader indications that the company estimates could drive peak annual sales of the product to approximately $600 million. Full Story. |
|
|
|
|
